Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066926 | 1.00 | MAPT (0.40) | MAPTTP53THRBSMN1; SMN2CARM1 | |
| SCHEMBL4564032 | 0.91 | MAPT (0.44) | MAPTTP53THRBSMN1; SMN2CARM1 | |
| SCHEMBL5066928 | 0.84 | CARM1 (0.41) | CARM1 | |
| SCHEMBL5066927 | 0.84 | CARM1 (0.41) | CARM1 | |
| SCHEMBL4563214 | 0.82 | CARM1 (0.41) | CARM1 | |
| SCHEMBL4563215 | 0.82 | CARM1 (0.41) | CARM1 | |
| SCHEMBL5070508 | 0.80 | CARM1 (0.53) | MAPTTP53THRBSMN1; SMN2CARM1 | |
| SCHEMBL5070507 | 0.80 | CARM1 (0.53) | MAPTTP53THRBSMN1; SMN2CARM1 | |
| SCHEMBL4563437 | 0.77 | ADORA3 (0.37) | MAPTSMN1; SMN2 | |
| SCHEMBL4563438 | 0.77 | ADORA3 (0.37) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | MAPT 71/4885TP53 559/4885THRB 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.